loperamide has been researched along with Irritable Bowel Syndrome in 37 studies
Loperamide: One of the long-acting synthetic ANTIDIARRHEALS; it is not significantly absorbed from the gut, and has no effect on the adrenergic system or central nervous system, but may antagonize histamine and interfere with acetylcholine release locally.
loperamide : A synthetic piperidine derivative, effective against diarrhoea resulting from gastroenteritis or inflammatory bowel disease.
Irritable Bowel Syndrome: A disorder with chronic or recurrent colonic symptoms without a clearcut etiology. This condition is characterized by chronic or recurrent ABDOMINAL PAIN, bloating, MUCUS in FECES, and an erratic disturbance of DEFECATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We examined the pharmacological profile of ramosetron, a 5-HT(3)-receptor antagonist for irritable bowel syndrome with diarrhea, comparing it with those of other 5-HT(3)-receptor antagonists, alosetron and cilansetron, and the anti-diarrheal agent loperamide." | 7.74 | Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome. ( Akuzawa, S; Funatsu, T; Hirata, T; Keto, Y; Sasamata, M, 2007) |
| "The aim of this study was to establish a pathophysiologic model of irritable bowel syndrome, and then to evaluate the pharmaceutical efficacy of ramosetron, a potent serotonin 3 (5-HT(3)) receptor antagonist, and other anti-irritable bowel syndrome agents in this model." | 7.74 | Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats. ( Akuzawa, S; Funatsu, T; Hirata, T; Keto, Y; Sasamata, M; Takeuchi, A, 2007) |
| " Rates of adverse events were comparable in both groups (37." | 6.90 | Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study. ( Brenner, DM; Cash, BD; Elmes, SJR; Gutman, CR; Jo, E; Liu, LWC; Sayuk, GS, 2019) |
| "Irritable bowel syndrome is categorized into one of three main categories: IBS with diarrhea, IBS with constipation, and IBS with mixed bowel habits." | 6.53 | Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS. ( Lacy, BE, 2016) |
| "Irritable bowel syndrome with diarrhea (IBS-D) is often managed with over-the-counter therapies such as loperamide, though with limited success." | 5.24 | Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use. ( Cash, BD; Chey, WD; Covington, PS; Dove, LS; Lacy, BE; Lembo, AJ, 2017) |
| "Loperamide is an effective therapy for a variety of diarrheal syndromes, including acute, nonspecific (infectious) diarrhea; traveler's diarrhea; and chemotherapy-related and protease inhibitor?associated diarrhea." | 4.84 | The role of loperamide in gastrointestinal disorders. ( Hanauer, SB, 2008) |
| "Fatty acid binding protein 4 inhibitor, BMS309403, was administered acutely or chronically for 6 and 13 consecutive days and its effect on GI transit was assessed in physiological conditions and in loperamide-induced constipation." | 3.88 | FABP4 blocker attenuates colonic hypomotility and modulates white adipose tissue-derived hormone levels in mouse models mimicking constipation-predominant IBS. ( Cygankiewicz, A; Fichna, J; Jacenik, D; Krajewska, WM; Małecka-Panas, E; Mokrowiecka, A; Mosińska, P; Pintelon, I; Sałaga, M; Sibaev, A; Storr, M; Timmermans, JP; Wasilewski, A, 2018) |
| " Nor has the efficacy of selective serotonin reuptake inhibitor antidepressants (SSRIs) been demonstrated; (5) Alosetron and tegaserod carry a risk of potentially life-threatening adverse effects and therefore have negative risk-benefit balances; (6) Seeds of plants such as psyllium and ispaghul, as well as raw apples and pears, have a limited impact on constipation and pain." | 3.75 | Irritable bowel syndrome: a mild disorder; purely symptomatic treatment. ( , 2009) |
| "We examined the pharmacological profile of ramosetron, a 5-HT(3)-receptor antagonist for irritable bowel syndrome with diarrhea, comparing it with those of other 5-HT(3)-receptor antagonists, alosetron and cilansetron, and the anti-diarrheal agent loperamide." | 3.74 | Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome. ( Akuzawa, S; Funatsu, T; Hirata, T; Keto, Y; Sasamata, M, 2007) |
| "The aim of this study was to establish a pathophysiologic model of irritable bowel syndrome, and then to evaluate the pharmaceutical efficacy of ramosetron, a potent serotonin 3 (5-HT(3)) receptor antagonist, and other anti-irritable bowel syndrome agents in this model." | 3.74 | Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats. ( Akuzawa, S; Funatsu, T; Hirata, T; Keto, Y; Sasamata, M; Takeuchi, A, 2007) |
| "We examined the effect of ramosetron, a potent serotonin (5-HT)(3)-receptor antagonist for irritable bowel syndrome with diarrhea, on conditioned fear stress (CFS)-induced defecation and normal (non-stressed) defecation in rats and compared ramosetron with the antidiarrheal agent loperamide and the spasmolytic agents trimebutine and tiquizium." | 3.74 | Inhibitory effects of ramosetron, a potent and selective 5-HT3-receptor antagonist, on conditioned fear stress-induced abnormal defecation and normal defecation in rats: comparative studies with antidiarrheal and spasmolytic agents. ( Akuzawa, S; Funatsu, T; Hirata, T; Keto, Y; Miyata, K; Sasamata, M, 2008) |
| " Rates of adverse events were comparable in both groups (37." | 2.90 | Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study. ( Brenner, DM; Cash, BD; Elmes, SJR; Gutman, CR; Jo, E; Liu, LWC; Sayuk, GS, 2019) |
| "Irritable bowel syndrome is categorized into one of three main categories: IBS with diarrhea, IBS with constipation, and IBS with mixed bowel habits." | 2.53 | Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS. ( Lacy, BE, 2016) |
| "Loperamide is an option for treatment of moderately severe diarrhea." | 2.43 | Treatment of irritable bowel syndrome. ( Gaarder, SM; Hadley, SK, 2005) |
| "For roflumilast, ID(50)s were 24." | 1.35 | Inhibition of phosphodiesterase type 4 decreases stress-induced defecation in rats and mice. ( Barone, FC; Barton, ME; Kikkawa, H; Kinoshita, M; Kuratani, K; Legos, JJ; Shimamura, M; White, RF, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (40.54) | 29.6817 |
| 2010's | 16 (43.24) | 24.3611 |
| 2020's | 6 (16.22) | 2.80 |
| Authors | Studies |
|---|---|
| Lembo, A | 1 |
| Sultan, S | 1 |
| Chang, L | 1 |
| Heidelbaugh, JJ | 1 |
| Smalley, W | 1 |
| Verne, GN | 1 |
| Selby, A | 1 |
| Reichenbach, ZW | 1 |
| Piech, G | 1 |
| Friedenberg, FK | 1 |
| Black, CJ | 1 |
| Houghton, LA | 1 |
| Ford, AC | 3 |
| Brenner, DM | 3 |
| Sayuk, GS | 3 |
| Gutman, CR | 2 |
| Jo, E | 2 |
| Elmes, SJR | 2 |
| Liu, LWC | 2 |
| Cash, BD | 3 |
| Twardowska, A | 1 |
| Fichna, J | 2 |
| Binienda, A | 1 |
| Abel, JL | 1 |
| Burslem, K | 1 |
| Azad, AK | 1 |
| Doolaanea, AA | 1 |
| Al-Mahmood, SMA | 1 |
| Kennedy, JF | 1 |
| Chatterjee, B | 1 |
| Bera, H | 1 |
| Touw, K | 1 |
| Ringus, DL | 1 |
| Hubert, N | 1 |
| Wang, Y | 1 |
| Leone, VA | 1 |
| Nadimpalli, A | 1 |
| Theriault, BR | 1 |
| Huang, YE | 1 |
| Tune, JD | 1 |
| Herring, PB | 1 |
| Farrugia, G | 1 |
| Kashyap, PC | 1 |
| Antonopoulos, DA | 1 |
| Chang, EB | 1 |
| Lacy, BE | 2 |
| Chey, WD | 1 |
| Lembo, AJ | 2 |
| Dove, LS | 1 |
| Covington, PS | 1 |
| Mosińska, P | 1 |
| Jacenik, D | 1 |
| Sałaga, M | 1 |
| Wasilewski, A | 1 |
| Cygankiewicz, A | 1 |
| Sibaev, A | 1 |
| Mokrowiecka, A | 1 |
| Małecka-Panas, E | 1 |
| Pintelon, I | 1 |
| Storr, M | 1 |
| Timmermans, JP | 1 |
| Krajewska, WM | 1 |
| Major, GAD | 1 |
| Gunn, D | 1 |
| Fashner, J | 1 |
| Gitu, AC | 1 |
| Besson, S | 1 |
| Hookway, C | 1 |
| Buckner, S | 1 |
| Crosland, P | 1 |
| Longson, D | 1 |
| Nee, J | 1 |
| Zakari, M | 1 |
| Morgan, B | 1 |
| Talley, NJ | 1 |
| Sood, MR | 1 |
| Vandvik, PO | 2 |
| Wald, A | 1 |
| Garrigues Gil, V | 1 |
| Ortiz Bellver, V | 1 |
| Mertz, HR | 1 |
| Taneja, I | 1 |
| Deepak, KK | 1 |
| Poojary, G | 1 |
| Acharya, IN | 1 |
| Pandey, RM | 1 |
| Sharma, MP | 1 |
| Kimball, ES | 1 |
| Palmer, JM | 1 |
| D'Andrea, MR | 1 |
| Hornby, PJ | 1 |
| Wade, PR | 1 |
| Hadley, SK | 1 |
| Gaarder, SM | 1 |
| Mearin, F | 1 |
| Hirata, T | 3 |
| Keto, Y | 3 |
| Funatsu, T | 3 |
| Akuzawa, S | 3 |
| Sasamata, M | 3 |
| Takeuchi, A | 1 |
| Barone, FC | 1 |
| Barton, ME | 1 |
| White, RF | 1 |
| Legos, JJ | 1 |
| Kikkawa, H | 1 |
| Shimamura, M | 1 |
| Kuratani, K | 1 |
| Kinoshita, M | 1 |
| Hanauer, SB | 2 |
| Miyata, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double Blind, Placebo Controlled, Cross Over Study to Investigate the Effectiveness and Safety of Eluxadoline in the Treatment of Diabetic Diarrhea[NCT04313088] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2022-07-01 | Withdrawn (stopped due to This study did not enroll any subjects) | ||
| Effects of Rifaximin on Visceral Hypersensitivity in Irritable Bowel Syndrome[NCT03462966] | Phase 2 | 4 participants (Actual) | Interventional | 2018-07-01 | Terminated (stopped due to recruitment challenges) | ||
| Efficacy and Safety of Paroxetine Controlled Release for Major Depressive Disorder in Irritable Bowel Syndrome Patients: An Open-label, Randomized, add-on Study[NCT01916200] | Phase 4 | 0 participants (Actual) | Interventional | 2014-01-31 | Withdrawn (stopped due to This study was Cancelled Before Active) | ||
| The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome- a Double Blind, Placebo - Controlled, Randomized Study[NCT01779765] | Phase 4 | 130 participants (Anticipated) | Interventional | 2013-01-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Association of urgency symptom and rectal sensitivity will be evaluated by the mean change in the balloon pressure (measured in mmHg) that leads to first urge sensation to defecate, evaluated based on the visual analogue scale defined in the primary outcome measure. (NCT03462966)
Timeframe: After completing 14-day course of rifaximin.
| Intervention | Millimetre of mercury (Mean) |
|---|---|
| Therapeutic | 106 |
A 100-cubic centimeter visual analogue scale with verbal descriptors (0=no sensation, 20=first sensation, 40=first sense of urge, 60=normal urge to defecate, 80=severe urge to defecate, and 100=discomfort/pain) will be used to score evoked sensations. (NCT03462966)
Timeframe: After completing 14-day course of rifaximin.
| Intervention | volume cubic centimeter (Mean) |
|---|---|
| Therapeutic | 37.5 |
"Normalization of lactulose breath test as a potential predictor of improvement of rectal hypersensitivity will be evaluated by comparing lactulose breath test results pre- and post-treatment.~Normalization of lactulose breath test defined as rise of hydrogen <20 Parts per million within 90 minutes of lactulose ingestion.~patients with positive" (NCT03462966)
Timeframe: After completing 14-day course of rifaximin
| Intervention | Participants (Count of Participants) |
|---|---|
| Therapeutic | 2 |
14 reviews available for loperamide and Irritable Bowel Syndrome
| Article | Year |
|---|---|
Pathophysiology, Differential Diagnosis, and Treatment of Diabetic Diarrhea.
Topics: Antidiarrheals; Autonomic Nervous System Diseases; Blind Loop Syndrome; Celiac Disease; Diabetes Mel | 2019 |
Enkephalinases as a new pharmacological target in the treatment of gastrointestinal tract disorders
Topics: Antidiarrheals; Diarrhea; Gastrointestinal Diseases; Humans; Inflammatory Bowel Diseases; Irritable | 2020 |
Chronic diarrhoea in adults: what not to miss.
Topics: Adenocarcinoma; Adenoma; Antidiarrheals; Bile Acids and Salts; Celiac Disease; Chronic Disease; Colo | 2019 |
Common gastrointestinal symptoms: irritable bowel syndrome.
Topics: Antidepressive Agents; Cognitive Behavioral Therapy; Diagnosis, Differential; Diet; Exercise Therapy | 2013 |
Irritable bowel syndrome in adults in primary care: summary of updated NICE guidance.
Topics: Antidepressive Agents, Tricyclic; Antidiarrheals; Constipation; Diarrhea; Diet Therapy; Humans; Irri | 2015 |
Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.
Topics: Antidepressive Agents, Tricyclic; Antidiarrheals; Carbolines; Diarrhea; Gastrointestinal Agents; Hum | 2015 |
Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS.
Topics: Antidiarrheals; Carbolines; Diarrhea; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel S | 2016 |
Irritable bowel syndrome.
Topics: Antidepressive Agents, Tricyclic; Colonic Diseases, Functional; Humans; Hypnosis; Irritable Bowel Sy | 2010 |
Irritable bowel syndrome.
Topics: Humans; Irritable Bowel Syndrome; Loperamide; Parasympatholytics | 2012 |
Irritable bowel syndrome--diarrhoea.
Topics: Anti-Bacterial Agents; Antidepressive Agents, Tricyclic; Antidiarrheals; Constipation; Defecation; D | 2012 |
Irritable bowel syndrome.
Topics: Antidepressive Agents, Tricyclic; Antidiarrheals; Dietary Fiber; Female; Humans; Irritable Bowel Syn | 2003 |
Irritable bowel syndrome.
Topics: Antidepressive Agents, Tricyclic; Antidiarrheals; Dietary Fiber; Female; Humans; Irritable Bowel Syn | 2003 |
Irritable bowel syndrome.
Topics: Antidepressive Agents, Tricyclic; Antidiarrheals; Dietary Fiber; Female; Humans; Irritable Bowel Syn | 2003 |
Irritable bowel syndrome.
Topics: Antidepressive Agents, Tricyclic; Antidiarrheals; Dietary Fiber; Female; Humans; Irritable Bowel Syn | 2003 |
Treatment of irritable bowel syndrome.
Topics: Adult; Antidiarrheals; Diagnosis, Differential; Female; Humans; Irritable Bowel Syndrome; Loperamide | 2005 |
[Drug treatment of irritable bowel syndrome: an unmet need].
Topics: Abdominal Pain; Analgesics; Antidepressive Agents, Tricyclic; Antidiarrheals; Carbolines; Controlled | 2007 |
The role of loperamide in gastrointestinal disorders.
Topics: Antidiarrheals; Diarrhea; Fecal Incontinence; Humans; Irritable Bowel Syndrome; Loperamide | 2008 |
3 trials available for loperamide and Irritable Bowel Syndrome
| Article | Year |
|---|---|
Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use.
Topics: Abdominal Pain; Adult; Antidiarrheals; Diarrhea; Double-Blind Method; Female; Gastrointestinal Agent | 2017 |
Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Diarrhea; Double-Blind Method; Female; Gastrointestinal | 2019 |
Yogic versus conventional treatment in diarrhea-predominant irritable bowel syndrome: a randomized control study.
Topics: Adult; Antidiarrheals; Diarrhea; Digestive System; Electrophysiology; Heart Rate; Humans; Irritable | 2004 |
20 other studies available for loperamide and Irritable Bowel Syndrome
| Article | Year |
|---|---|
AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea.
Topics: Antidepressive Agents, Tricyclic; Diarrhea; Gastrointestinal Agents; Humans; Irritable Bowel Syndrom | 2022 |
Efficacy of Eluxadoline in Irritable Bowel Syndrome With Diarrhea.
Topics: Diarrhea; Humans; Imidazoles; Irritable Bowel Syndrome; Loperamide; Phenylalanine | 2020 |
Response to Black et al.
Topics: Diarrhea; Humans; Imidazoles; Irritable Bowel Syndrome; Loperamide; Phenylalanine | 2020 |
Improved work productivity and health-related quality of life in patients with irritable bowel syndrome with diarrhea receiving eluxadoline following inadequate response to loperamide.
Topics: Absenteeism; Adolescent; Adult; Aged; Aged, 80 and over; Diarrhea; Female; Gastrointestinal Agents; | 2021 |
Electro-hydrodynamic assisted synthesis of lecithin-stabilized peppermint oil-loaded alginate microbeads for intestinal drug delivery.
Topics: Administration, Oral; Alginates; Animals; Anti-Inflammatory Agents; Disease Models, Animal; Drug Com | 2021 |
Mutual reinforcement of pathophysiological host-microbe interactions in intestinal stasis models.
Topics: Animals; Constipation; Fecal Microbiota Transplantation; Female; Gastrointestinal Microbiome; Host-P | 2017 |
FABP4 blocker attenuates colonic hypomotility and modulates white adipose tissue-derived hormone levels in mouse models mimicking constipation-predominant IBS.
Topics: Adipose Tissue, White; Animals; Behavior, Animal; Biphenyl Compounds; Colon; Constipation; Disease M | 2018 |
[Cognitive behavioral therapy of somatoform autonomic disorders].
Topics: Adaptation, Psychological; Adolescent; Arousal; Cognitive Behavioral Therapy; Diagnosis, Differentia | 2013 |
Drug development: A healthy pipeline.
Topics: Animals; Benzimidazoles; Benzofurans; Bile Acids and Salts; Carbolines; Colesevelam Hydrochloride; C | 2016 |
Board Review Vignette: Irritable Bowel Syndrome.
Topics: Abdominal Pain; Adult; Anion Exchange Resins; Antidiarrheals; Carbolines; Cholestyramine Resin; Cons | 2016 |
Treatment approaches to irritable bowel syndrome.
Topics: Alprostadil; Anti-Bacterial Agents; Antidepressive Agents, Tricyclic; Behavior Therapy; Child; Child | 2009 |
Irritable bowel syndrome: a mild disorder; purely symptomatic treatment.
Topics: Acupuncture Therapy; Antidepressive Agents, Tricyclic; Carbolines; Clinical Trials as Topic; Constip | 2009 |
[Current and future prospects of the treatment of the irritable bowel syndrome].
Topics: Antidepressive Agents; Antidiarrheals; Forecasting; Health Services; Humans; Irritable Bowel Syndrom | 2003 |
Acute colitis induction by oil of mustard results in later development of an IBS-like accelerated upper GI transit in mice.
Topics: Acute Disease; Animals; Antidiarrheals; Colitis; Colon; Diarrhea; Disease Models, Animal; Gastrointe | 2005 |
Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome.
Topics: Animals; Benzimidazoles; Carbazoles; Carbolines; Carrier Proteins; Colon; Defecation; Gastrointestin | 2007 |
Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats.
Topics: Animals; Behavior, Animal; Benzimidazoles; Carbazoles; Carbolines; Colon; Colonic Diseases, Function | 2007 |
Inhibition of phosphodiesterase type 4 decreases stress-induced defecation in rats and mice.
Topics: Aminopyridines; Animals; Antidiarrheals; Benzamides; Cold Temperature; Cyclopropanes; Defecation; Ga | 2008 |
The benefits of loperamide in the treatment of patients with IBS or IBD. Introduction.
Topics: Antidiarrheals; Humans; Inflammatory Bowel Diseases; Irritable Bowel Syndrome; Loperamide | 2007 |
Inhibitory effects of ramosetron, a potent and selective 5-HT3-receptor antagonist, on conditioned fear stress-induced abnormal defecation and normal defecation in rats: comparative studies with antidiarrheal and spasmolytic agents.
Topics: Animals; Antidiarrheals; Benzimidazoles; Conditioning, Classical; Defecation; Fear; Irritable Bowel | 2008 |
[Time and again digestion problems. What really helps in irritable bowel syndrome?].
Topics: Antidiarrheals; Antifoaming Agents; Carum; Cholestyramine Resin; Dietary Fiber; Flatulence; Humans; | 2005 |